Min Jung Koh

5PUBLICATIONS
89CO-AUTHORS
Haematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 17, 2025
Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas.

Josie G Ford, Min Jung Koh, Alexandra W Lenart

|Oct 31, 2024
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium.

Jessy Xinyi Han, Min Jung Koh, Leora Boussi

|Jan 22, 2024
KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes.

Bimarzhan Assatova, Robert Willim, Christopher Trevisani

|Jul 11, 2022
Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis.

Nazila Shafagati, Min J Koh, Leora Boussi

|Jan 13, 2022
Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas.

Min Jung Koh, Mwanasha H Merrill, Min Ji Koh

Pageof 1

Frequent Collaborators

5 joint publications

Salvia Jain

3 joint publications

Robert Stuver

3 joint publications

Francine M Foss

3 joint publications

Mwanasha Merrill